Connacht Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Connacht Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$242K	Sell	24,155 -14,876	-38%	-$163K	1.43%	42
2023 Q2	$485K	Buy	39,031 +8,062	+26%	+$109K	0.66%	28
2023 Q1	$434K	Buy	30,969 +3,283	+12%	+$47.2K	0.19%	81
2022 Q4	$396K	Buy	27,686 +15,779	+133%	+$248K	0.18%	84
2022 Q3	$304K	Buy	11,907 +3,972	+50%	+$99.7K	0.22%	95
2022 Q2	$225K	Sell	7,935 -1,760	-18%	-$55.8K	0.09%	134
2022 Q1	$342K	Sell	9,695 -6,856	-41%	-$230K	0.18%	105
2021 Q4	$693K	Sell	16,551 -12,018	-42%	-$487K	0.68%	54
2021 Q3	$1.4M	Buy	+28,569	New	+$1.39M	0.91%	36

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Connacht Asset Management's MRVI Position: Q3 2023 in Review

Connacht Asset Management reduced its Maravai LifeSciences (MRVI) stake by 38% in Q3 2023, selling an estimated $163K and leaving 24,155 shares worth $242K. The position accounts for 1.43% of the portfolio, ranked #42.

Connacht Asset Management first reported a position in MRVI in Q3 2021 and has held it in 9 quarters since. The position peaked at $1.4M in Q3 2021. 205 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

Connacht Asset Management held 24,155 shares of Maravai LifeSciences worth $242K as of Q3 2023.
Connacht Asset Management sold 14,876 Maravai LifeSciences shares in Q3 2023, an estimated $163K.
Maravai LifeSciences made up 1.43% of Connacht Asset Management's portfolio in Q3 2023, its #42 holding.
Connacht Asset Management first reported a position in Maravai LifeSciences in Q3 2021 and has held it in 9 quarters since.
Connacht Asset Management's Maravai LifeSciences position peaked at $1.4M in Q3 2021.
205 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.